- BioNTech SE BNTX has reported Q2 FY22 revenues of €3.19 billion, down from €5.3 billion a year ago and €6.37 billion in Q1 FY22.
- BioNTech believes the development of the pandemic remains dynamic, causing a re-phasing of orders and leading to fluctuations in quarterly revenues.
- This revenue fluctuation caused by the re-phasing of orders is expected to remain over the rest of the financial year with uptake in demand in key markets in Q4 FY22 related to the Omicron-adapted bivalent vaccine, subject to regulatory approval.
- Related: EU Urges Pfizer To Further Delay COVID-19 Vaccine Deliveries: Reuters.
- EPS of €6.45 ($6.872) missed the consensus of $7.36.
- The company and its partner Pfizer Inc PFE signed an agreement with the U.S. government to provide additional 105 million doses of COVID-19 vaccine with an option for another 195 million doses.
- BioNTech and Pfizer will start a clinical trial of a Covid-19 vaccine adapted to the BA.4 and BA.5 variants of omicron in August.
- Outlook: BioNTech reaffirms FY22 COVID-19 vaccine revenues of €13 billion - €17 billion as the doses scheduled for delivery in June through August will now be delivered in September through to Q4 FY22.
- BioNTech has started manufacturing bivalent Omicron BA.1- and BA.4/5-adapted vaccines and expects to be able to start delivering shots targeted at BA.4 and BA.5 as early as October if it receives regulatory approval.
- Price Action: BNTX shares are down 4.98% at $173.99 during the premarket session on the last check Monday.
- Photo by x3 from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
